This inventor holds 2 USPTO granted patents and 1 published patent application. Top assignee: Asahi Kasei Kabushiki Kaisha. Active years: 2026.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2026
Title: The Innovations of Toru Katsumata
Introduction
Toru Katsumata is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work with hyaluronic acid derivatives. With a total of 2 patents to his name, Katsumata continues to push the boundaries of medical science.
Latest Patents
Katsumata's latest patents include a hyaluronic acid derivative and a pharmaceutical composition. The first patent presents a hyaluronic acid derivative that incorporates a steryl group, characterized by a weight-average molecular weight to number-average molecular weight ratio of 1.11 or more and 10.0 or less. The second patent details a hyaluronic acid derivative composition that consists of a hyaluronic acid derivative with a steryl group and a polar group-containing compound. This composition is designed to enhance the efficacy of pharmaceutical applications by conjugating one or more drugs to the hyaluronic acid derivative.
Career Highlights
Katsumata is associated with Asahi Kasei Kabushiki Kaisha, a leading company in the chemical and pharmaceutical industry. His work has been instrumental in developing new therapeutic solutions that leverage the unique properties of hyaluronic acid.
Collaborations
Throughout his career, Katsumata has collaborated with notable colleagues, including Yoshiyuki Nakagawa and Kohei Yabuuchi. These partnerships have fostered a creative environment that encourages innovation and the advancement of medical technologies.
Conclusion
Toru Katsumata's contributions to the field of pharmaceuticals through his patents on hyaluronic acid derivatives exemplify his commitment to innovation. His work not only enhances the understanding of drug delivery systems but also paves the way for future advancements in medical treatments.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile